insidermonkey.comSEP 222 min read$TEM

Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test

Goldman Sachs initiated Tempus AI (TEM) with a Neutral rating and $75 target. Q2 revenue rose 22% YoY to $382.5M, with Diagnostics up 20% and Data/Applications up 28%. Tempus extended its partnership with Recursion (RXRX) through 2029. FDA approvals could boost future revenue. Short interest is high at 29.17% of float.

Original reporting

insidermonkey.com

Published Sep 22, 2026, 9:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 22, 2026, 9:28 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test — source image — Source · insidermonkey.com

Decision brief

The 30-second read

$TEMBullishMed

Why it matters

The coverage may prompt short covering and modest buying, but investors should monitor upcoming contract renewals.

Market read

Analyst initiation and contract extension provide fresh catalysts for Tempus AI, potentially influencing short‑term price action.

What to watch

High short interest and potential competitive pressure from larger genomics firms.

Relevance 8/10Novelty 8/10Timing: today

Background

Goldman Sachs initiated coverage of Tempus AI, noting strong diagnostics growth and a new data‑licensing contract, while flagging renewal risk for existing data contracts.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBullishMedium confidence

Context

Goldman Sachs initiated coverage with a $75 price target and noted a $42M committed payment extension with Recursion Pharmaceuticals through 2029.

Expected impact

Potential modest upside if diagnostics growth continues; downside risk if data contracts fail to renew.

Evidence & confidence

Target above current price suggests upside, but high short interest and contract renewal uncertainty temper confidence.

Market effects

Sector

Highlights growing importance of AI‑driven diagnostics and data platforms in healthcare.

Regional

US biotech sector may see modest interest as analysts evaluate data‑licensing models.

Global

Contract extension with Recursion, a biotech partner, underscores cross‑border collaborations in precision medicine.

Counterpoint

What could challenge this read

Renewal risk for data contracts could pressure the stock despite the analyst target.

Key entities

Company
Tempus AI, Inc.
US‑listed biotech providing diagnostics and data platforms.
Company
Recursion Pharmaceuticals
Partner in a data‑licensing agreement extended through 2029.
Analyst
Goldman Sachs
Issued a $75 price target and initiated coverage.

Read at source ← All news

SEP 17

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min

SEP 17

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min

SEP 15

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min

SEP 5

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min

SEP 2

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min